10x Genomics Delivers ‘Single Cell for a Single Cent’ with New Chromium Launches

PLEASANTON, Calif., Oct. 15, 2024 /PRNewswire/ — 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced today the launch of two new Chromium products intended to democratize access to single cell analysis. The new offerings – GEM-X Flex and GEM-X Universal Multiplex – introduce significant improvements in performance, workflow and cost effectiveness, enabling more researchers to pursue single cell analysis for more applications.

These launches are part of the company’s strategy to drive widespread adoption of single cell analysis by lowering customer costs in multiple directions: per cell, per sample, per experiment and per project. With these advances, 10x Genomics is addressing the growing demand for high-throughput single cell applications and providing cost-effective offerings to help new researchers getting started in single cell and existing labs looking to scale up their research.

“These launches are an integral part of our ongoing push to democratize single cell analysis and make it more accessible and more affordable for more researchers than ever before,” said Michael Schnall-Levin, Founding Scientist and Chief Technology Officer at 10x Genomics. “They add to a growing list of new single cell products, protocols and capabilities that make 2024 the most exciting year of Chromium innovation in the platform’s history. We can’t wait to see how labs of all sizes take advantage of the leading performance, scalability and affordability of our GEM-X portfolio to fuel their research.”

GEM-X Flex: Superior performance and ultra low cost per cell

GEM-X Flex Gene Expression brings 10x Genomics’ highest performing and most flexible assay – Chromium Flex – to the company’s new GEM-X technology architecture, delivering superior performance and substantial cost savings and enabling single cell analysis at mega scale.

Since its initial launch in 2022, Chromium Flex has delivered class-leading performance across a broad range of sample types and became the first and only commercial single cell assay compatible with FFPE samples. Now on the GEM-X architecture, Flex adds the scalability to run millions of cells for less than $0.01 per cell. The company believes GEM-X Flex is the most cost effective single cell product available for high-throughput applications, including mega-scale CRISPR screens, cell atlassing projects and multi-site translational studies, among others.

Key Performance Specifications:

Ultimate flexibility for low cost at any scale: Researchers can benefit from the highest sequencing efficiency to reduce total project costs, as well as fix, batch and run samples on their own schedule without compromising on data quality.
Built for mega scale: With GEM-X Flex, researchers can profile up to 2.5 million cells per run and 5 million cells per kit, for a cost as low as $0.01 per cell.
Unlock previously inaccessible sample types: Flex is the only single cell assay compatible with a wide range of sample types: fresh, frozen, PFA-fixed tissue, whole blood, and FFPE samples.
Improved sample recovery: With new input recommendations as low as 25,000 cells per sample, GEM-X Flex delivers a four-fold improvement in sample recovery and enables researchers to explore limited samples like small tissue biopsies and flow-sorted cells.

“Chromium Flex has set a new standard in routine sample preservation for our core facility users, offering a flexible and reliable way to preserve biological material for future analysis. We’ve already sequenced hundreds of samples and likely have a multitude more biobanked in the freezer, ready for future studies,” said Niels Vandamme, Head of VIB Single Cell Core (Ghent University and KU Leuven). “The GEM-X Flex workflow is truly the best of both worlds. Researchers can now take advantage of enhanced sample fixation protocols that require lower cell input while benefiting from GEM-X’s improved cell capture capabilities. This workflow opens up new possibilities for both small-scale and high-throughput projects.”

GEM-X Flex Gene Expression, compatible exclusively with Chromium iX and X instruments, is now shipping to customers globally.

GEM-X Universal Multiplex: Easy on-chip multiplexing delivers significantly lower per sample cost

10x Genomics is also introducing new on-chip multiplexing capabilities for its flagship GEM-X Universal 3′ and 5′ Gene Expression assays, enabling researchers to run more cost-effective single cell studies even at small scale.

With GEM-X Universal Multiplex, researchers can batch and run four independent samples, up to 5,000 cells per sample, for approximately $560 per sample. On-chip multiplexing allows researchers to combine cells from up to four samples directly on the chip and collect the partitioned cells in one recovery well, simplifying the workflow and reducing hands-on time compared to other sample multiplexing methods. After sequencing, the samples are distinguished through computational demultiplexing to streamline the process.

Key Performance Specifications:

Exceptional performance and superior data quality: GEM-X Universal Multiplex delivers performance consistent with the company’s flagship GEM-X 3′ and 5′ Gene Expression kit s.
Significantly lower per sample cost: Perform single cell analysis for approximately $560 per sample, expanding access to a wider range of labs and research projects.
Broad sample compatibility: Analyze diverse species and sample types incompatible with other multiplexing methods. The GEM-X Universal 3′ and 5′ assays are also compatible with upstream fixation for flexible sample processing and storage.
Easy multiplexing workflow: 10x Genomics’ unique, on-chip multiplexing workflow eliminates the need for upstream sample tagging and enables high cell recovery with low cell input requirements, ideally suited for limited samples including organoids and stem cells.

“GEM-X Universal Multiplex not only drives large-scale, high-throughput projects, but also lowers barriers for new users,” added Vandamme. “Its clean multiplexing strategy enables affordable entry into the field without the complexity of additional labeling requirements, making it ideal for pilot experiments and easier to scale. On-chip multiplexing simplifies workflows while making single cell sequencing more accessible to all.”

GEM-X Universal 3′ Gene Expression Multiplex is compatible with Chromium Xo and X instruments. GEM-X Universal 5′ Gene Expression Multiplex is exclusively available on Chromium X instruments. All GEM-X Universal Multiplex assays are now available for pre-order and are expected to begin shipping later this quarter.

About 10x Genomics10x Genomics is a life science technology company building products to accelerate the mastery of biology and advance human health. Our integrated solutions include instruments, consumables and software for single cell and spatial biology, which help academic and translational researchers and biopharmaceutical companies understand biological systems at a resolution and scale that matches the complexity of biology. Our products are behind breakthroughs in oncology, immunology, neuroscience and more, fueling powerful discoveries that are transforming the world’s understanding of health and disease. To learn more, visit 10xgenomics.com or connect with us on LinkedIn or X (Twitter).

Forward Looking StatementsThis press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 as contained in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which fall under the “safe harbor” provisions of those sections. All statements, other than statements of historical facts, may be forward-looking statements. Forward-looking statements generally can be identified by the use of forward-looking terminology such as “may,” “might,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “potential” or “continue” or variations of them or similar terminology, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements include statements regarding 10x Genomics, Inc.’s (“10x Genomics”) product launches, performance, scale, configuration, costs, capabilities, adoption and pipeline. These statements are based on management’s current expectations, forecasts, beliefs, assumptions and information currently available to management, and actual outcomes and results could differ materially from these statements due to a number of factors. Other risks and uncertainties that could affect 10x Genomics’ financial and operating results and cause actual results to differ materially from those indicated by the forward-looking statements made in this press release include those discussed under the captions “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and elsewhere in the documents 10x Genomics files with the Securities and Exchange Commission (the “SEC”) from time to time. Although 10x Genomics believes that the expectations reflected in the forward-looking statements are reasonable, it cannot provide any assurance that these expectations will prove to be correct nor can it guarantee that the future results, levels of activity, performance and events and circumstances reflected in the forward-looking statements will be achieved or occur. The forward-looking statements in this press release are based on information available to 10x Genomics as of the date hereof, and 10x Genomics disclaims any obligation to update any forward-looking statements provided to reflect any change in its expectations or any change in events, conditions or circumstances on which any such statement is based, except as required by law. These forward-looking statements should not be relied upon as representing 10x Genomics’ views as of any date subsequent to the date of this press release.

Disclosure Information10x Genomics uses filings with the Securities and Exchange Commission, our website (www.10xgenomics.com), press releases, public conference calls, public webcasts and our social media accounts as means of disclosing material non-public information and for complying with our disclosure obligations under Regulation FD.

ContactsInvestors: [email protected]Media: [email protected]

SOURCE 10x Genomics, Inc.